Biotech News
Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress
CTIM-76 weekly dosing at 140–280 µg in heavily pretreated PROC: 22% confirmed ORR, 56% confirmed DCR, and median PFS of 5.6 months Dose escalation to 420 µg every three weeks is ongoing following completion of the DLT assessment period at 280 µg Phase 1b initiation expected in Q1 2027 and initial
